Conatus Pharmaceuticals (CNAT) Shares Pop Higher on Positive Zika Virus Mention

August 29, 2016 11:58 AM EDT

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Conatus Pharmaceuticals (NASDAQ: CNAT) shares pop higher amid positive WSJ mention regarding Zika virus.

UPDATE - The article notes Zika virus therapies recently published in the journal Nature Medicine.

Conatus has several patents for the liver-disease drug emricasan, which couldbe used as a potential treatment. Some of the patents don't expire until 2028.

Conatus is up 18 percent.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

FDA, Trader Talk

Add Your Comment